See more : The Rowe Companies, Inc. (ROWC) Income Statement Analysis – Financial Results
Complete financial analysis of 3SBio Inc. (TRSBF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of 3SBio Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- AB Volvo (publ) (VOLV-A.ST) Income Statement Analysis – Financial Results
- Oruka Therapeutics Inc. (ORKA) Income Statement Analysis – Financial Results
- Medicover AB (publ) (MCOV-B.ST) Income Statement Analysis – Financial Results
- Excel Industries Limited (EXCELINDUS.BO) Income Statement Analysis – Financial Results
- Signify N.V. (SFFYF) Income Statement Analysis – Financial Results
3SBio Inc. (TRSBF)
About 3SBio Inc.
3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People's Republic of China. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; EPIAO and SEPO recombinant human erythropoietins to treat anemia; and Cipterbin for HER2-positive metastatic breast cancer in combination with chemotherapy. It also offers Mandi to treat male alopecia and alopecia areata; Xenopax for preventing acute rejection after renal transplant; Byetta for the glycemic control in patients with type 2 diabetes; Qiming Keli to treat retinopathy caused by type 2 diabetic; Aiyishu for iron-deficiency anemia; and SPARIN, an injectable low-molecular-weight heparin calcium for the treatment of prophylaxis and deep vein thrombosis, as well as for the prevention of clotting during hemodialysis. In addition, it offers Intefen, a recombinant human interferon to treat lymphatic or hematopoietic malignancies and viral infections; and Inleusin, a human interleukin2 for the treatment of renal cell carcinoma, melanoma, and thoracic fluid build-up. Further, the company provides trading, project management and consultation, technology, and agricultural services. It has collaboration agreements with companies, such as AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and DanaFarber Cancer Institute. The company was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.82B | 6.86B | 6.38B | 5.59B | 5.32B | 4.58B | 3.73B | 2.80B | 1.67B | 1.13B | 875.40M | 656.15M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.17B | 1.19B | 1.11B | 1.06B | 925.35M | 877.26M | 676.24M | 402.27M | 241.91M | 87.48M | 83.18M | 70.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 6.64B | 5.67B | 5.28B | 4.52B | 4.39B | 3.71B | 3.06B | 2.40B | 1.43B | 1.04B | 792.22M | 585.64M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 84.98% | 82.69% | 82.67% | 80.98% | 82.60% | 80.86% | 81.89% | 85.62% | 85.54% | 92.26% | 90.50% | 89.25% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 794.79M | 693.17M | 753.87M | 590.34M | 526.57M | 362.71M | 257.31M | 243.01M | 111.32M | 96.38M | 93.51M | 73.56M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 480.83M | 384.73M | 371.49M | 452.78M | 676.01M | 316.75M | 315.11M | 301.24M | 301.04M | 170.77M | 71.11M | 73.98M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 3.01B | 2.58B | 2.32B | 2.02B | 1.95B | 1.69B | 1.33B | 1.02B | 585.59M | 431.43M | 340.64M | 304.42M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.49B | 2.96B | 2.70B | 2.47B | 2.63B | 2.01B | 1.65B | 1.32B | 886.63M | 602.20M | 439.09M | 386.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 0.00 | -2.94M | 49.88M | -75.06M | -26.28M | -26.48M | -20.41M | 2.32M | 2.55M | 3.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 4.18B | 3.65B | 3.50B | 2.99B | 3.13B | 2.38B | 1.87B | 1.48B | 969.42M | 690.24M | 601.24M | 480.94M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost & Expenses | 5.46B | 4.84B | 4.61B | 4.05B | 4.05B | 3.25B | 2.54B | 1.88B | 1.21B | 777.73M | 684.42M | 551.45M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Income | 153.12M | 150.66M | 98.65M | 84.50M | 83.86M | 64.77M | 21.77M | 23.96M | 33.53M | 24.09M | 17.73M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 212.30M | 101.05M | 66.53M | 81.07M | 109.48M | 138.38M | 141.35M | 147.71M | 26.55M | 29.18M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 334.85M | 369.78M | 329.00M | 360.94M | 333.97M | 313.26M | 243.70M | 161.00M | 77.36M | 33.49M | 40.00M | 30.49M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | 2.53B | 2.75B | 2.26B | 1.59B | 1.67B | 1.54B | 1.34B | 981.09M | 680.64M | 376.81M | 318.70M | 163.49M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Ratio | 32.31% | 40.32% | 35.91% | 28.51% | 31.40% | 38.33% | 37.47% | 38.25% | 33.23% | 36.55% | 36.41% | 24.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 2.46B | 2.38B | 1.96B | 1.23B | 1.34B | 1.44B | 1.16B | 908.85M | 478.70M | 379.79M | 278.70M | 133.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income Ratio | 31.45% | 34.75% | 30.75% | 22.05% | 25.12% | 31.50% | 30.94% | 32.49% | 28.61% | 33.58% | 31.84% | 20.27% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -479.91M | 204.39M | -93.93M | -252.73M | -112.84M | 51.57M | -88.30M | -65.85M | -21.71M | -19.61M | -50.91M | -2.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | 1.98B | 2.27B | 1.87B | 979.13M | 1.22B | 1.50B | 1.10B | 850.07M | 587.86M | 360.18M | 208.71M | 130.41M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 25.31% | 33.15% | 29.28% | 17.52% | 23.00% | 32.63% | 29.51% | 30.39% | 35.14% | 31.85% | 23.84% | 19.87% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 392.17M | 366.02M | 241.19M | 208.02M | 242.79M | 218.27M | 177.61M | 135.81M | 61.63M | 68.46M | 112.65M | 28.52M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | 1.55B | 1.92B | 1.65B | 835.79M | 973.72M | 1.28B | 935.39M | 712.56M | 526.28M | 291.73M | 95.89M | 101.67M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Ratio | 19.82% | 27.93% | 25.87% | 14.96% | 18.31% | 27.86% | 25.05% | 25.47% | 31.45% | 25.80% | 10.95% | 15.49% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.62 | 0.78 | 0.65 | 0.33 | 0.38 | 0.46 | 0.37 | 0.28 | 0.23 | 0.15 | 0.05 | 0.66 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.63 | 0.74 | 0.62 | 0.33 | 0.38 | 0.46 | 0.36 | 0.28 | 0.23 | 0.15 | 0.05 | 0.64 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 2.48B | 2.58B | 2.67B | 2.75B | 2.54B | 2.75B | 2.54B | 2.52B | 2.26B | 1.94B | 1.94B | 154.73M | 153.31M | 151.24M | 150.61M | 151.66M | 145.74M | 101.65M | 102.44M | 94.59M | 700.01M |
| Weighted Avg Shares Out (Dil) | 2.44B | 2.65B | 2.77B | 2.75B | 2.54B | 2.75B | 2.65B | 2.56B | 2.30B | 1.94B | 1.94B | 158.97M | 157.15M | 154.13M | 151.03M | 151.71M | 145.74M | 700.01M | 700.01M | 700.01M | 700.01M |
Source: https://incomestatements.info
Category: Stock Reports